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INTRODUCTION 
Recent advances in Novel Drug Delivery System (NDDS) 
aims to enhance safety and efficacy of drug molecule by 
formulating a convenient dosage form for administration 
and to achieve better patient compliance. One such 
approach is Fast Dissolving Tablet (ODT). 1-4 
The term ODT appears in the European Pharmacopoeia 
defined as ‘‘uncovered tablet for buccal cavity, where it 
disperses before ingestion”. The solid ODT dosage form 
turns into a soft paste or liquid form for easy swallowing, 
and thus it is free of suffocation risk. ODTs are beneficial 
for paediatric, geriatric, schizophrenic, bedridden patients 
and those with Parkinsonism or developmentally disabled 
patients with persistent nausea and patients who have little 
or no access to water. ODT will avoid missing out of dose 
even during travelling, busy or other situations where there 
is no access to water. They undergo disaggregation in the 
mouth when in contact with the saliva in less than 60 
seconds, preferably in less than 40 seconds, forming a 
suspension which is easy to swallow. A major claim of 
some oral dispersible tablets is increased bioavailability 
compared to traditional tablets because some of the drugs 
are absorbed from the mouth, pharynx and esophagus as 
the saliva passes down into the stomach. In such cases, the 
bioavailability of the drug is significantly increased over 
those observed in the conventional tablet dosage form. 5-8 
MATERIALS AND METHODS  
Sublimation method 
Specified quantity of Cinnarizine, camphor, mannitol, 
aspartame, talc and magnesium stearate were weighed 
accurately and were passed through 60 # screen prior to 
mixing. All the materials were transferred to mortar and 
triturated till it mixed uniformly. The resulting powder 
mixture was compressed into tablets using single punch 
tablet machine. The tablets were dried at 60oC oven till 
constant weigh obtained. 9-10 
EVALUATION OF POWDER BLEND
 
Table 1: Evaluation of the Powder Blend 
Batch code Bulk density Tapped density Angle of repose % compressibility Hausner ratio 
B1 0.58 0.68 25.61 14.71 1.172 
B2 0.56 0.67 25.07 16.42 1.196 
B3 0.55 0.64 24.68 14.06 1.164 
B4 0.53 0.62 24.50 14.52 1.170 
B5 0.52 0.59 23.82 11.86 1.135 
B6 0.50 0.57 23.49 12.28 1.140 
B7 0.58 0.70 30.05 17.14 1.207 
B8 0.58 0.71 30.64 18.31 1.224 
B9 0.59 0.73 31.45 19.18 1.237 
 
 
 
 
ABSTRACT 
Oral Dispersible tablets (ODTs) constitute an innovative dosage form, which overcomes the problem of swallowing and 
provides a quick onset of action. The aim of the proposed work is to formulate fast dissolving tablets of Cinnarizine for rap id 
dissolution of drug and absorption, which may produce rapid onset of action in the treatment of motion sickness. For this 
purpose the tablets of Cinnarizine were prepared by Effervescent method, Super disintegrants addition method and Sublimation 
method. Cinnarizine is an Antihistamines drug has been used for the treatment of motion sickness. Cinnarizine is poorly 
soluble in water making it a potent candidate fast-dissolving drug delivery system.  
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Formulation of Oral Dispersible Tablet 
Table 2: Formulation of ODT 
Ingredient B1 B2 B3 B4 B5 B6 B7 B8 B9 
Cinnarizine 25 25 25 25 25 25 25 25 25 
Crospovidone
 
10 15 20  - - - - - 
Croscarmellose 
sodium 
- - - 10 15 20 - - - 
L-HPC - - - - - - 10 15 20 
Avicel 102 60 60 60 60 60 60 60 60 60 
Aspartame 2 2 2 2 2 2 2 2 2 
Talc 4 4 4 4 4 4 4 4 4 
Mg stearate 2 2 2 2 2 2 2 2 2 
Mannitol up to… 200 200 200 200 200 200 200 200 200 
 
EVALUATION OF ORAL DISPERSIBLE TABLETS 
Table 3: physical parameters of mouth dissolving Tablet 
Batch 
Code 
Weight 
Variation 
Thickness 
(mm) 
Hardness 
(Kg/cm
2
) 
Friability 
(%) 
In-Vitro Disin. 
Time (Sec) 
Wetting 
Time (Sec) 
Assay (%) 
B1 pass 2.56 2.5 0.73 48.3 ±1.53 69.8 ±1.04 98.14 
B2 pass 2.57 2.5 0.76 34.0 ±1.00 35.0 ±0.95 99.02 
B3 pass 2.60 2.5 0.79 28.6 ±1.22 32.4 ±1.15 100.51 
B4 pass 2.63 2.5 0.74 59.4 ±2.42 89.0 ±0.85 98.91 
B5 pass 2.65 3.0 0.78 32.6 ±1.25 66.0 ±1.35 100.04 
B6 pass 2.66 2.5 0.80 36.6 ±2.12 70.4 ±1.48 99.86 
B7 pass 2.51 3.0 0.69 59.7 ±2.46 67.8 ±0.35 98.92 
B8 pass 2.52 2.5 0.65 33.5 ±0.50 41.7 ±1.45 101.05 
B9 pass 2.54 2.5 0.66 25.3 ±0.58 29.1 ±1.05 100.34 
 
3. In-vitro Disintegration time 
The in-vitro disintegration time was determined using 
disintegration test apparatus. A tablet was placed in each 
of the six tubes of the apparatus and one disc was added to 
each tube. The time in seconds taken for complete 
disintegration of the tablet with no palatable mass 
remaining in the apparatus was measured in seconds. 11
 
Table 4: Evaluation parameter of mouth dissolving tablets prepared by different method 
Parameters Effervescent Superdisintegrant addition Sublimation 
Hardness  (kg/cm2) 2.5 2.5 2.5 
Friability (%) 0.625 0.764 0.861 
Disintegration time (s) 92 34 132 
 
The disintegration time and friability were evaluated and results were graphically summarized in the Figure 1 and Figure 2 
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Figure 1: Column graph of friability of mouth dissolving 
tablets prepared by different method 
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Figure 2: Column graph of disintegration time of mouth 
dissolving tablets prepared by different method
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The friability of tablets, prepared by various methods was 
shown in Fig. No 1. Friability of all batches was in the 
range of standard limit (less than 1%) and no more 
significant difference. It can be concluded that tablets 
prepared by superdisintegrant addition method has less 
disintegration time than other method. 
12-15
 
STUDY OF THE EFFECT OF CONCENTRATION 
OF AVICEL PH 102 
The intermediate concentration of the diluent (Avicel PH 
102), that is, 20 - 50 % of the tablet weight was selected 
from the trial series. These trial batches were prepared by 
super disintegrant addition method with same process as 
above.16-17 
Table 5: Composition of formulation of Trial series 
Ingredient T1 T2 T3 T4 
Cinnarizine 25 25 25 25 
Crospovidone 15 15 15 15 
Avicel PH 102 40 60 80 100 
Aspartame 2 2 2 2 
Talc 4 4 4 4 
Mg stearate 2 2 2 2 
Mannitol up to… 200 200 200 200 
All the quantities are in mg. 
These tablets were evaluated for hardness, friability and disintegration time. The procedure was same as above evaluation 
tests.  
Table 6: Evaluation parameter of Trial series 
Parameter T1 T2 T3 T4 
Hardness (kg/cm2) 2.5 2.5 2.5 2.5 
Friability (%) 2.24 0.76 0.62 0.45 
Disintegration time (s) 27 34 48 64 
 
The friability and disintegration time were evaluated and results are graphically summarized in the Fig. No 3 and Fig. No 
4. 
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Figure 3: Column graph of the % Friability of trial series 
0
10
20
30
40
50
60
70
T1 T2 T3 T4
Batch No.
D
is
in
te
gr
at
io
n 
tim
e 
(S
ec
)
 
Figure 4: Column graph of the Disintegration time (Sec) 
of trial series 
 
8. In-Vitro drug release: 
Release of the drug in vitro, was determined by estimating 
the dissolution profile. 
Dissolution test:  
Standard USP or IP dissolution apparatus have been used 
to study in vitro release profile using rotating paddle.In 
vitro release rate study of mouth dissolving tablet of 
Cinnarizine was carried out using the Apparatus 2 (Paddle 
apparatus) method. The dissolution apparatus was covered 
with the black color polythine to protect the solution from 
light. The dissolution test was carried out using 900 ml of 
0.1 N HCl, at 37 + 0.50C and 50 rpm. A sample (5 ml) of 
the solution was withdrawn from the dissolution apparatus 
at 2, 4, 6, 8 and 10 min and withdrawn volume was 
replaced with fresh dissolution media. 18-20 
The withdrawn samples diluted with dissolution medium 
and then filter it with whattman filter paper and assayed at 
253.5 nm. The % release of Cinnarizine was calculated.
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Table 6: Percentage Cumulative drug release profile of batch B1 
Time 
(min) 
Absorb
ance 
Concentratio
n (µg/ml) 
Amt. in 5 ml 
(mg/ml) 
Amt. in 900 ml 
(mg/ml) 
Cumulative drug release 
in 900 ml (mg) 
Cumulative % 
drug release 
0 0 0 0 0 0 0 
2 0.0764 1.46 0.0073 13.12 13.12 52.49 
4 0.1178 2.25 0.0112 20.23 20.24 80.96 
6 0.1387 2.65 0.0132 23.82 23.84 95.36 
8 0.1422 2.71 0.0136 24.42 24.46 97.82 
10 0.1425 2.72 0.0136 24.48 24.52 98.08 
 
Table 7: Percentage Cumulative drug release profile of batch B2 
Time 
(min) 
Absorb
ance 
Concentratio
n (µg/ml) 
Amt. in 5 ml 
(mg/ml) 
Amt. in 900 ml 
(mg/ml) 
Cumulative drug release 
in 900 ml (mg) 
Cumulative % 
drug release 
0 0 0 0 0 0 0 
2 0.0968 1.85 0.0092 16.63 16.63 66.50 
4 0.1262 2.41 0.0120 21.68 21.68 86.74 
6 0.1416 2.70 0.0135 24.32 24.34 97.37 
8 0.1438 2.74 0.0137 24.70 24.73 98.93 
10 0.1439 2.75 0.0137 24.72 24.76 99.06 
 
Table 8: Percentage Cumulative drug release profile of batch B3 
Time 
(min) 
Absorb
ance 
Concentratio
n (µg/ml) 
Amt. in 5 ml 
(mg/ml) 
Amt. in 900 ml 
(mg/ml) 
Cumulative drug release 
in 900 ml (mg) 
Cumulative % 
drug release 
0 0 0 0 0 0 0 
2 0.1021 1.95 0.0097 17.54 17.54 70.15 
4 0.1294 2.47 0.0123 22.23 22.23 88.94 
6 0.1452 2.77 0.0139 24.94 24.96 99.84 
8 0.1459 2.78 0.0139 25.06 25.10 100.38 
10 0.146 2.79 0.0139 25.08 25.13 100.50 
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Figure 5: Cumulative drug release profile of batch B1, B2 and B3 
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Table 9: Percentage Cumulative drug release profile of batch B9 
Time 
(min) 
Absorbance Concentration 
(µg/ml) 
Amt. in 5 ml 
(mg/ml) 
Amt. in 900 ml 
(mg/ml) 
Cumulative drug 
release in 900 ml (mg) 
Cumulative % 
drug release 
0 0 0 0 0 0 0 
2 0.1211 2.31 0.0116 20.80 20.80 83.20 
4 0.1397 2.67 0.0133 23.99 24.01 96.02 
6 0.1452 2.77 0.0139 24.94 24.96 99.86 
8 0.1456 2.78 0.0139 25.01 25.05 100.19 
10 0.1455 2.78 0.0139 24.99 25.04 100.17 
 
COMPARISON OF BEST FORMULATED TABLET WITH MARKETED TABLET 
The best formulated tablet was then compared with marketed tablet STUGERON 25mg. Formulation B9 was compared 
with marketed tablet for in vitro dissolution study.   
Table 10: Percentage Cumulative drug release profile of Marketed Tablet 
Time 
(min) 
Absorbance Concentration 
(µg/ml) 
Amt. in 5 ml 
(mg/ml) 
Amt. in 900 ml 
(mg/ml) 
Cumulative drug 
release in 900ml (mg) 
Cumulative % 
drug release 
0 0 0 0 0 0 0 
2 0.0326 0.62 0.0031 5.60 5.60 22.40 
4 0.0365 0.70 0.0035 6.27 6.27 25.09 
6 0.0462 0.88 0.0044 7.94 7.94 31.77 
8 0.0602 1.15 0.0057 10.34 10.35 41.40 
10 0.0731 1.40 0.0070 12.56 12.57 50.29 
15 0.0993 1.90 0.0095 17.06 17.08 68.32 
30 0.1307 2.49 0.0125 22.45 22.48 89.93 
45 0.1453 2.77 0.0139 24.96 25.00 100.01 
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Figure 6: Comparison of in-vitro dissolution of B9 with marketed tablet 
SUMMARY AND CONCLUSION 
The present study was undertaken with an aim to formulate 
and evaluate Fast Dissolving tablets of Cinnarizine using 
Sublimation method with the addition of 
superdisintegranting agents. To increase the dissolution 
rate of poorly soluble drug Cinnarizine, by using the 
addition of Avicel 102 as Superdisintegrants. 
Preformulation study was carried out initially and results 
directed for the further course of formulation. Various 
formulations of Fast Dissolving tablets Cinnarizine were 
formulated by using various super Disintegrants—
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Crosspovidone, Sodium Starch Glycolate, Crosscarmellose 
Sodium. The tablets were evaluated for physical parameter 
such as Hardness, thickness, weight variation, friability, in-
vitro disintegration, wetting time and In-Vitro Dissolution. 
Disintegration time of optimized formulation B9 was 
compared to conventional tablets, where it observed that 
disintegration time less than market preparation.
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